Servier, announced the acquisition of Pixuvri from CTI BioPharma. Pixuvri is a treatment for adult patients with multiply relapsed or...
The European Commission has given conditional marketing authorization for Pixuvri (pixantrone), from Cell Therapeutics, as monotherapy for the treatment of...
NICE (The National Institute for Health and Care Excellence) has finally recommended Pixuvri (pixantrone)) from Cell Therapeutics for the treatment...
NICE has issued draft guidance not recommending the use of Pixuvri (pixantrone), from Cell Therapeutics, for an aggressive form of...
Servier Laboratories and CTI BioPharma Corp.,jointly announced that they have entered into an exclusive license and collaboration agreement to develop...
The FDA has accepted the resubmission of Pixuvri(pixantrone dimaleate) from Cell Therapeutics as a single-agent treatment of patients with relapsed...
New results have been released from the Phase III trial of Pixuvri (pixantrone dimaleate), from Cell Therapeutics, for patients with...
NICE has issued second draft guidance on Pixuvri (pixantrone), from Cell Therapeutics, as a treatment of adult patients with multiply...
Servier announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued...
The CHMP has given a conditional recommendation for the approval of Pixuvri (pixantrone dimaleate) from CTI Life Sciences for relapsed...